Brain Cancer Cells Attract Stem Cells for Angiogenesis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

New research shows that in order to grow, gliomas attract stem cells circulating in the blood to develop new blood vessels, as well as using blood vessels from the brain itself.

COLUMBUS, Ohio—New research shows that in order to grow, gliomas attract stem cells circulating in the blood to develop new blood vessels, as well as using blood vessels from the brain itself. The animal study found that in gliomas, about 75% of new blood vessels in the tumor come from the surrounding brain, but that about 25% come from progenitor cells. The research also showed that the progenitor cells are drawn to the tumor because the tumor cells secrete stromal-derived factor-1 (SDF-1), a factor that regulates vasculogenesis.

"These findings indicate that blocking blood vessel growth in tumors will probably require multiple drugs, some that inhibit the growth of blood vessels coming from the surrounding brain and co-opted into the tumor, and some that inhibit blood vessels that form from endothelial progenitor cells," said principal investigator, E. Antonio Chiocca, MD, PhD, professor of neurological surgery and co-director of Ohio State University's Dardinger Center for Neuro-oncology. The research, published online September 15 in the journal Cancer Research, was largely performed while Dr. Chiocca was at Massachusetts General Hospital and Harvard Medical School, in collaboration with Drs. David Scadden, Manish Aghi, and Kenneth Cohen.

The researchers transferred fluorescent tagged bone marrow cells from one set of mice into another in which the bone marrow was destroyed. Mouse glioma cells were then implanted into the animals' brains and under the skin. As the tumors grew, blood vessels that developed from the progenitor cells fluoresced, while those that developed from the brain did not. Further research showed that "if the tumor doesn't make SDF-1, the progenitor cells won't travel to it," Dr. Chiocca commented.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.